Kymera Therapeutics: Intriguing Degradation Thesis, But A Bit Powder Puff

Group 1 - The article discusses the performance of Kymera Therapeutics (NASDAQ: KYMR), noting a significant decline in stock price from $46 to$31, representing a 33% drop, after reaching a high of over $50 in November 2024 [1] - The investing group Haggerston BioHealth provides insights into the biotech, pharma, and healthcare sectors, offering catalysts, buy and sell ratings, and detailed financial analyses for major pharmaceutical companies [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group and has compiled extensive reports on more than 1,000 companies in the sector [1]